David Einhorn Gain Therapeutics, Inc. Transaction History
Greenlight Capital Inc
- $1.97 Billion
- Q4 2023
A detailed history of David Einhorn (Greenlight Capital Inc) transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Greenlight Capital Inc holds 588,410 shares of GANX stock, worth $917,919. This represents 0.1% of its overall portfolio holdings.
Number of Shares
588,410
Previous 546,560
7.66%
Holding current value
$917,919
Previous $2.45 Million
21.41%
% of portfolio
0.1%
Previous 0.12%
Shares
2 transactions
Others Institutions Holding GANX
# of Institutions
23Shares Held
2.39MCall Options Held
10KPut Options Held
0-
Dme Capital Management, LP New York, NY566KShares$883,1620.04% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny335KShares$521,9630.01% of portfolio
-
Geode Capital Management, LLC Boston, MA272KShares$424,2760.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA145KShares$226,5380.0% of portfolio
-
Telemetry Investments, L.L.C. New York, NY123KShares$191,8800.61% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $18.5M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...